CoChat

Seamless Oncology-Drug Development

Prowell, Tatiana M., Theoret, Marc R., Pazdur, Richard · 2016 · New England Journal of Medicine

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Interview with Dr. Alice Shaw on a new model for accelerating the development of promising oncology drugs. (10:06)Download Increasingly, firms developing cancer drugs are forgoing standard phased development for a seamless approach of adding cohorts to a first-in-human trial to study doses and activity in various cancers. Key regulatory interactions and protections may therefore be missing.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmp1603747

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

Cited by 126

Metadata

Authors
Prowell, T. M., Theoret, M. R., & Pazdur, R.
Affiliations
United States Food and Drug Administration (US)
Venue
New England Journal of Medicine
Published
2016-05-26
Volume
374
Issue
21
Pages
2001-2003
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2339302618
Cited by
126
References
0
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 17 · 2022: 6 · 2021: 14 · 2020: 6 · 2019: 14 · 2018: 27 · 2017: 23 · 2016: 9
FWCI
24.61
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
anticancer drug development, accelerated drug development, regulatory interactions, anticancer agents, dose escalation
MeSH terms
Antineoplastic Agents, Clinical Trials as Topic, Humans, Neoplasms, United States, United States Food and Drug Administration, Drug Approval, Therapeutic Human Experimentation, Drug Discovery, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Seamless Oncology-Drug Development. https://app.cochat.ai/papers/10.1056/nejmp1603747
The paper
Prowell, T. M., Theoret, M. R., & Pazdur, R. (2016). Seamless Oncology-Drug Development. New England Journal of Medicine. https://doi.org/10.1056/nejmp1603747

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.